H-Pro-Phe-Gly-Lys-OH | 21957-31-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: H-Pro-Phe-Gly-Lys-OH
• 英文别名: (2S)-6-amino-2-[[2-[[(2S)-3-phenyl-2-[[(2S)-pyrrolidine-2-carbonyl]amino]propanoyl]amino]acetyl]amino]hexanoic acid
• CAS: 21957-31-3
• 化学式: C₂₂H₃₃N₅O₅
• 分子量: 447.5
• InChiKey: VMILMCIMLLYNMB-BZSNNMDCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.2
• 重原子数：
  32
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  163
• 氢给体数：
  6
• 氢受体数：
  7

文献信息

• Method for characterising polypeptides
  申请人：Xzillion GmbH & CO.KG

  公开号：EP1265072A1

  公开（公告）日：2002-12-11

  Provided is a method for characterising a polypeptide or a population of polypeptides, which method comprises the steps of: (a) Optionally reducing disulphide linkages in the polypeptides, if they are present, and capping free thiols in the polypeptides, if they are present; (b) contacting a sample comprising one or more polypeptides with a sequence specific cleavage reagent which cleaves one or more polypeptides on the C-terminal side of a lysine residue to produce peptide fragments; (c) optionally deactivating the cleavage reagent; (d) contacting the sample with a lysine reactive agent to cap ε-amino groups; (e) removing those peptides having capped ε-amino groups; and (f) recovering the C-terminal peptides

  提供了一种表征多肽或多肽种群的方法，该方法包括以下步骤： (a) 可选地还原多肽中的二硫键（如果存在），并封闭多肽中的游离巯基（如果存在）； (b) 用序列特异性切割试剂接触含有一个或多个多肽的样品，该试剂在赖氨酸残基的C-末端侧切割一个或多个多肽以产生肽片段； (c) 可选地去活化切割试剂； (d) 用赖氨酸反应试剂接触样品以封闭ε-氨基团； (e) 去除具有已封闭ε-氨基团的肽片段； (f) 回收C-末端肽片段。
• Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (TAFI) and methods of use thereof
  申请人：——

  公开号：US20020177560A1

  公开（公告）日：2002-11-28

  The invention is directed in part to a purified form of stabilized activated thrombin-activatable fibrinolysis inhibitor (TAFIa). The invention is further directed to a method of producing stabilized TAFIa. The invention is also directed to methods for therapeutic use of stabilized TAFIa such as in the treatment, prevention or management of diseases via an anti-coagulant effect. The invention is also directed to methods for therapeutic use of inhibitors of TAFIa such as in the treatment, prevention or management of diseases via a procoagulant effect. The invention is also directed to methods of diagnostic use of stabilized TAFIa such as a standard in a chromogenic or a fluorometric carboxypeptidase activity assay. The present invention is also directed to kits comprising stabilized TAFIa useful in measuring carboxypepetidase activity.

  本发明部分涉及一种纯化形式的稳定活化凝血酶可激活纤溶抑制剂（TAFIa）。本发明进一步涉及生产稳定化 TAFIa 的方法。本发明还涉及稳定TAFIa的治疗使用方法，例如通过抗凝作用治疗、预防或控制疾病。本发明还涉及 TAFIa 抑制剂的治疗使用方法，例如通过促凝血作用治疗、预防或控制疾病。本发明还涉及稳定的 TAFIa 的诊断使用方法，如在显色或荧光羧肽酶活性测定中用作标准品。本发明还涉及用于测量羧肽酶活性的试剂盒，其中包含稳定的 TAFIa。
• METHOD OF PREPARATION OF STABILIZED THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) AND METHODS OF USE THEREOF
  申请人：AMERICAN DIAGNOSTICA, INC.

  公开号：EP1383885A1

  公开（公告）日：2004-01-28
• EP1383885A4
  申请人：——

  公开号：EP1383885A4

  公开（公告）日：2005-11-30
• CHARACTERISING POLYPEPTIDES
  申请人：Xzillion GmbH & Co. KG

  公开号：EP1397684A2

  公开（公告）日：2004-03-17